Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
AESTHETIC MEDICAL INTERNATIONAL HOLDINGS GROUP LIMITED ANNOUNCES PRICING OF INITIAL PUBLIC OFFERING
-
UPDATE: Pre-Open Movers 10/25: (ACRS) (BOOM) (CHTR) Higher (VCRA) (PCG) (AMZN) Lower (more...)
-
UPDATE: Cantor Fitzgerald Starts MannKind (MNKD) at Buy
-
Cantor Fitzgerald Downgrades Vocera Communications (VCRA) to Neutral
-
Cantor Fitzgerald Starts Pfenex Inc. (PFNX) at Overweight
-
Orchid Island Capital Announces Third Quarter 2019 Results
-
PayPal (PYPL) PT Lowered to $125 at Cantor Fitzgerald
-
Alkermes (ALKS) PT Lowered to $22 at Cantor Fitzgerald
-
Cantor Fitzgerald Defends ArQule (ARQL)
-
Biogen (BIIB) PT Raised to $300 at Cantor Fitzgerald on 30% Aducanumab POS
-
Advantage Lithium Corp. (AAL:CN) (AVLIF) PT Lowered to Cdn$0.70 at Cantor Fitzgerald
-
Centene (CNC) PT Lowered to $80 at Cantor Fitzgerald
-
Union Acquisition Corp. II Announces Closing of $200 Million Initial Public Offering
-
PlacementTracker Publishes Q3 2019 PIPE and Private Placement Markets League Tables
-
Cantor Fitzgerald Reiterates Overweight Rating on Kadmon (KDMN) Following KOL Call
-
Cantor Fitzgerald Assumes Mesoblast Limited (MESO) at Overweight
-
Cantor Fitzgerald Assumes Aldeyra Therapeutics (ALDX) at Overweight
-
Cantor Fitzgerald Assumes Aerie Pharma (AERI) at Overweight
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Sep 30
-
Cantor Fitzgerald Assumes Marinus Pharmaceuticals (MRNS) at Overweight, PT $7
-
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Union Acquisition Corp. II (LATN) Prices 17.5M Unit IPO at $10/Unit
-
Union Acquisition Corp. II Announces Pricing of $175 Million Initial Public Offering
-
Orchid Island Capital Announces October 2019 Monthly Dividend and September 30, 2019 RMBS Portfolio Characteristics
-
Cantor Fitzgerald Reiterates Positive View on Amarin (AMRN) Following Final ICER Report
-
Pre-Open 10/17: (LLNW) (NFLX) (AA) Higher (TEUM) (TXT) (IBM) Lower (more...)
-
UPDATE: Cantor Fitzgerald Starts ArQule (ARQL) at Overweight
-
After-Hours Movers 10/16: (LLNW) (NFLX) (CSX) Higher; (IBM) (URI) Lower (more...)
-
Cantor Fitzgerald Transfers Coverage on Evofem Biosciences Inc (EVFM) at Overweight
-
Cantor Fitzgerald Reiterates Overweight Rating on UnitedHealth Group (UNH) Post Q3
-
Cantor Fitzgerald Reiterates Overweight Rating on Repay (RPAY) Following APS Acquisition
-
Reata Pharmaceuticals (RETA) PT Raised to $180 at Cantor Fitzgerald on Favorable MOXIe Data
-
Cantor Fitzgerald Starts Exagen (XGN) at Overweight
-
Makor Securities London Ltd Receive Regulatory (FCA) Approval to Operate an Organized Trading Facility ('OTF'), Providing Service Continuity to All Clients Across Products, Venues and Execution Protoc
-
Cantor Fitzgerald Upgrades GlaxoSmithKline (GSK:LN) (GSK) to Buy
-
Freddie Mac Prices $489 Million Multifamily KG-Deal, K-G02
-
Cantor Fitzgerald Starts Endava PLC (ADR) (DAVA) at Neutral
-
Positive 12-Month Data a Major De-Risking Event for ProQR Therapeutics N.V. (PRQR) QR-110 - Cantor Fitzgerald
-
Mission Rock Residential Assumes Management of Nashville Apartments
-
Hamilton Zanze Acquires Rivertop Apartments in Nashville
-
Cantor Fitzgerald Reiterates Overweight Rating on Global Blood Therapeutics (GBT) Following Analyst Day
-
Institute for Portfolio Alternatives Elects New Board Members for 2020
-
UPDATE: Mereo BioPharma (MREO) Receives FDA Fast Track Designation for Navicixizumab for Treatment of Heavily Pretreated Ovarian Cancer
-
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
-
Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer
-
Nevakar Enters into $17.5 Million Product Financing Agreement with H.I.G. Capital Partners for Continued Development of Injectable Products
-
Regulators fine New York's BGC Partners $25 million for forex options fraud
-
R.W. Pressprich Continues to Build Fixed Income Credit Team
-
Kindred Biosciences Secures $50 Million Debt Facility with Solar Capital Partners
-
Fennec to Present at the 2019 Cantor Global Healthcare Conference on October 4, 2019

